PTSM: Pharmaceutical Technology Sourcing and Management
CMC Biologics will manufacture monoclonal antibodies (mAbs) and provide process development services for the PATH Malaria Vaccine Initiative.
CMC Biologics will manufacture monoclonal antibodies (mAbs) and provide process development services for the PATH Malaria Vaccine Initiative (MVI), CMC announced on Aug. 12, 2015. The company will use its proprietary production cell line for the project, and will test MVI’s investigational mAb for its ability to target circumsporozoite protein (CSP) and protect against infection by Plasmodium falciparum, the parasite that causes malaria.
"We will deliver cGMP material for MVI's preclinical and Phase I/II clinical studies in a remarkable 12 months-the fastest development timeline in the industry from DNA to delivery," Gustavo Mahler, PhD, global chief operations officer at CMC Biologics said in a press release.
Based on the success of the project with MVI, the group may hire CMC to investigate additional mAbs that bind to alternate epitopes. "Assuming this initial study is successful, we will evaluate other antibodies targeting novel vaccine targets for their capacity to protect humans from infection and therefore, inform future vaccine development efforts," confirmed Ashley J. Birkett, PhD, director at MVI.
Source: CMC Biologics
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.